Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000599186 | SCV000709805 | pathogenic | not provided | 2018-02-16 | criteria provided, single submitter | clinical testing | The c.626+1 G>A splice site variant in the EXT2 gene has been previously reported in at least one individual with multiple exostoses (Vink et al., 2005; Wuyts et al., 2005). This variant destroys the canonical splice donor site in intron 3, and is expected to cause abnormal gene splicing. This variant is not observed in large population cohorts (Lek et al., 2016). Alternate nucleotide changes at the same position (c.626+1G>T, c.626+1G>C) have been reported in association with hereditary multiple exostoses (Lonie et al., 2006; Xu et al., 2017). |
Labcorp Genetics |
RCV001062683 | SCV001227498 | pathogenic | Exostoses, multiple, type 2 | 2020-02-06 | criteria provided, single submitter | clinical testing | Disruption of this splice site has been observed in individuals affected with multiple osteochondromas (PMID: 15586175, 17041877, 29529714, 28849184). This splice site is also known as c.725+1G in the literature. ClinVar contains an entry for this variant (Variation ID: 503618). This variant is not present in population databases (ExAC no frequency). This sequence change affects a donor splice site in intron 3 of the EXT2 gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in EXT2 are known to be pathogenic (PMID: 10679937, 19810120). For these reasons, this variant has been classified as Pathogenic. |